Using Conjoint Analysis to Evaluate Health State Preferences

  • Sheryl L. SzeinbachEmail author
  • James H. Barnes
  • William F. McGhan
  • Matthew M. Murawski
  • Ron Corey


Quality of life dimensions are important considerations when patients evaluate pharmaceutical products with respect to personal benefits. Traditionally, standard gamble, time trade-off, and rating scale techniques are used to obtain preference (utility) estimates for various quality of life dimensions. This study examines three objectives to determine the feasibility of using conjoint analysis to elicit patient preferences for a particular health state. For the first objective, patients with multiple myeloma were asked to select quality of life conditions for 18 hypothetical patients with cancer and to indicate which conditions were the easiest and hardest to live with. Second, patients were asked to rate several cancer-related and general symptoms using visual analog scales. Third, comparisons were made between the two techniques to determine similarity and validity. Results revealed that conjoint analysis is useful for health-related quality of life research, and that conjoint analysis results compare favorably with values obtained from visual analog scales.

Key Words

Health state preferences Conjoint analysis Visual analog scaling Quality of life multiple myeloma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nunnally JC. Psychometric Theory. 2nd ed. New York: McGraw-Hill; 1978.Google Scholar
  2. 2.
    Von Neumann J, Mergenstem O. Theory of Games and Economic Behavior. 2nd ed. Princeton, NJ: University Press; 1947.Google Scholar
  3. 3.
    Keeney RL, Raiffa H. Decisions with Multiple Objectives. New York, NY: Cambridge University Press; 1993:131–139.CrossRefGoogle Scholar
  4. 4.
    Luce RD, Tukey JW. Simultaneous conjoint measurement: A new type of fundamental measurement. J Mathematical Psychol. 1964;1:1–27.CrossRefGoogle Scholar
  5. 5.
    Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Med Cure. 1996;34(7):702–722.CrossRefGoogle Scholar
  6. 6.
    Addington-Hall JM. MacDonald LD, Anderson HR. Can the Spitzer quality of life index help to reduce prognostic uncertainty in terminal care? Br J Cancer. 1990;62:695–699.CrossRefGoogle Scholar
  7. 7.
    Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shephard R, Battista Renaldo N, Catchlove BR. Measuring the quality of life of cancer patients. J Chron Dis. 1981;34:585–597.CrossRefGoogle Scholar
  8. 8.
    Coates A, Thomson D, McLeod GRM, Hersey P, Gill PG, Olver IN, Kefford R, Lowenthal RM, Beadle G, Walpole E. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. European J Cancer. 1993;29A(12):1731–1734.CrossRefGoogle Scholar
  9. 9.
    Wilson IB, Cleary PC. Linking clinical variables with health-related quality of life: A conceptual mode) of patient outcomes. JAMA. 1995;273(1): 59–65.CrossRefGoogle Scholar
  10. 10.
    The EuroQol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRefGoogle Scholar
  11. 11.
    Uyl-de Groot CA, Rutten FFH, Bonsel GJ. Measurement and valuation of quality of life in economic appraisal of cancer treatment. Eur J Cancer. 1994; 30A:111–117.CrossRefGoogle Scholar
  12. 12.
    Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Quality Life Res. 1993;2:319–325.CrossRefGoogle Scholar
  13. 13.
    Brazier J, Jones N. Kind P. Testing the validity of the F.uroqol and comparing it with the SF-36 Health Survey questionnaire. Qual Life Res. 1993:2:169–180.CrossRefGoogle Scholar
  14. 14.
    Ahles TA. Ruckdeschel JC, Blanchard EB. Caner-related pain-11. Assessment with visual analogue scales. J Psychosom Res. 1984;28:121–124.CrossRefGoogle Scholar
  15. 15.
    Price DD, Bush HM, Long S, et al. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain. 1994;56:217–226.CrossRefGoogle Scholar
  16. 16.
    Guyatt GH, Townsend M, Berman LB, Keller JL. A comparison of likert and visual analogue scales for measuring change in funtion. J Chronic Dis. 1987; Vol 40(12):1129–1133.CrossRefGoogle Scholar
  17. 17.
    Drummond MF, Stoddart GL. Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications, Oxford University Press; 1992.Google Scholar
  18. 18.
    Thurstone LL. Attitudes can be measured. Am J Sociol. 1928;33:529–554.CrossRefGoogle Scholar
  19. 19.
    Gensch DH, Recker WW. The multinomial, multiat-tribute logit choice model. J Marketing Res. 1979; Vol XVI: 124–132.CrossRefGoogle Scholar
  20. 20.
    Szeinbach SL, Barnes JH. Garner DD. Building brand equity in the pharmaceutical industry through value-added services: an application of maximum difference conjoint analysis using best-worst scaling. J Business Res. 1997;40:226–236.Google Scholar
  21. 21.
    Horowitz JL, Louviere JJ. Testing predicted choices against observations in probabilistic discrete-choice models. Marketing Sci. 1993;12(3):270–279.CrossRefGoogle Scholar
  22. 22.
    Lynch JG. Uniqueness issues in the decompositional modeling of multiattribute overall evaluations: an information integration perspective. J Marketing Res. 1985;22:1–19.CrossRefGoogle Scholar
  23. 23.
    Louviere JJ, Finn A, Timmermans H. Retailing research. In McGraw-Hill Handbook of Marketing Research. New York: McGraw-Hill Book Company; 1992.Google Scholar
  24. 24.
    Louviere JJ, Swait J, Anderson D. Best-worst conjoint: theory, methods and comparisons with choicebased conjoint and reported marketplace choices. Working Paper. University of Florida, 1995.Google Scholar
  25. 25.
    Ware JE. Sherboume CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.CrossRefGoogle Scholar
  26. 26.
    McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36):II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–263.CrossRefGoogle Scholar
  27. 27.
    Jack W. Pharmaceutical differentiation through quality of life measurement: a case study. J Pharm Mark Man. 1991:6:65–85.CrossRefGoogle Scholar
  28. 28.
    Melzack R. The McGill pain questionniare; major properties and scoring methods. Pain. 1975; 1227–1299.Google Scholar
  29. 29.
    Ahles TA, Ruckdeschel JC, Blanchard EB. Caner-relted pain-II. Assessment with visual analogue scales. J Psychosom Res. 1984:28:121–124.CrossRefGoogle Scholar
  30. 30.
    Cresswell SM. English PJ, Roberts JT. Marsh MM. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol. 1995;76:360–365.CrossRefGoogle Scholar
  31. 31.
    Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 1979;47(2): 263–291.CrossRefGoogle Scholar
  32. 32.
    Krupnick AJ. Cropper M. The effect of information on health risk valuations. J Risk Uncertainty. 1992; 5:29–48.CrossRefGoogle Scholar
  33. 33.
    Viscusi W. Kip WM. Huber J. Pricing environmental health risks: A survey assessment of risk-risk and risk-dollar trade-offs for chronic bronchitis. J Environmental Econ Manage. 1991;21:32–51.CrossRefGoogle Scholar

Copyright information

© Drug Information Association, Inc 1999

Authors and Affiliations

  • Sheryl L. Szeinbach
    • 1
    Email author
  • James H. Barnes
    • 2
  • William F. McGhan
    • 3
  • Matthew M. Murawski
    • 4
  • Ron Corey
    • 5
  1. 1.College of PharmacyThe Ohio State UniversityColumbusUSA
  2. 2.School of Business AdministrationUniversity of MississippiUniversityUSA
  3. 3.Philadelphia College of Pharmacy and SciencePhiladelphiaUSA
  4. 4.Department of Pharmacy Practice, School of PharmacyPurdue UniversityWest LafayetteUSA
  5. 5.Economic Strategies, Global Business ManagementPharmacia & UpjohnBridgewaterUSA

Personalised recommendations